Although an established therapy for hypertension, effectively protecting patients against the early morning surge in blood pressure, clinical research with MICARDIS® continues.
The potential of MICARDIS® to provide cardiovascular protection is one of the many avenues of ongoing clinical investigation. Other areas under evaluation are the use of MICARDIS® to prevent end organ damage, to lower blood pressure in patients with hypertension and diabetes, and to provide cerebrovascular protection.
The information available via this section is investigational and does not reflect the current licensed indication for MICARDIS®. Please review the Product Information section of this website for information on licensed indications.
Cardiovascular Protection
Click here to find out more about MICARDIS® clinical research in cardiovascular protection, including The ONTARGET® Trial Programme
End Organ Damage
Click here to find out more about MICARDIS® clinical research in end organ protection, including the DETAIL, TRENDY and VIVALDI trials
Hypertension
Click here to find out more about MICARDIS® clinical research in hypertension, including the ARBs-FDC and PRISMA I & II trials
Hypertension and Diabetes
Click here to find out more about MICARDIS® clinical research in hypertension and diabetes, including the INNOVATION and SMOOTH trials
Stroke Prevention
Click here to find out more about MICARDIS® clinical research in stroke protection and the PRoFESS® trial
Clinical Abstract Library
Click here to enter the Clinical Abstract Library where you can find further information on MICARDIS® clinical research
Calendar
Tools and Downloads
- Clinical Abstract Library
- Expert Interview Library
- ONTARGET® Results Webcast
- Free ONTARGET® Online Publication Download
- Cardiovascular Risk Guidelines
- Renin Angiotensin System in Cardiovascular Medicine Journal
My Alerts
You will shortly be able to create your own personal alerts service bringing the latest MICARDIS® news and updates direct to your inbox. Watch this space for more information.
